Use of (64)Cu-labeled fibronectin domain with EGFR-overexpressing tumor xenograft: molecular imaging.
暂无分享,去创建一个
[1] S. Ståhl,et al. Affibody Molecules for Epidermal Growth Factor Receptor Targeting In Vivo: Aspects of Dimerization and Labeling Chemistry , 2009, Journal of Nuclear Medicine.
[2] Zhen Cheng,et al. Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein. , 2010, Bioconjugate chemistry.
[3] Jinming Yu,et al. Assessment of 11C‐labeled‐4‐N‐(3‐bromoanilino)‐6, 7‐dimethoxyquinazoline as a positron emission tomography agent to monitor epidermal growth factor receptor expression , 2007, Cancer science.
[4] Matti Anniko,et al. Blocking EGFR in the liver improves the tumor-to-liver uptake ratio of radiolabeled EGF , 2010, Tumor Biology.
[5] Kazunori Kawamura,et al. [11C]Gefitinib ([11C]Iressa): Radiosynthesis, In Vitro Uptake, and In Vivo Imaging of Intact Murine Fibrosarcoma , 2010, Molecular Imaging and Biology.
[6] Quynh-Thu Le,et al. Cetuximab-Based Immunotherapy and Radioimmunotherapy of Head and Neck Squamous Cell Carcinoma , 2010, Clinical Cancer Research.
[7] Wendy S. Becker,et al. Reduction of the renal uptake of radiolabeled monoclonal antibody fragments by cationic amino acids and their derivatives. , 1995, Cancer research.
[8] Adam P. Silverman,et al. Evaluation of a 64Cu-Labeled Cystine-Knot Peptide Based on Agouti-Related Protein for PET of Tumors Expressing αvβ3 Integrin , 2010, Journal of Nuclear Medicine.
[9] Vladimir Tolmachev,et al. 111In-benzyl-DTPA-ZHER2:342, an affibody-based conjugate for in vivo imaging of HER2 expression in malignant tumors. , 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[10] A. Koide,et al. Monobodies: antibody mimics based on the scaffold of the fibronectin type III domain. , 2007, Methods in molecular biology.
[11] A. Haese*,et al. Clinical Significance of Epidermal Growth Factor Receptor Protein Overexpression and Gene Copy Number Gains in Prostate Cancer , 2007, Clinical Cancer Research.
[12] S. Gambhir,et al. Engineered knottin peptides: a new class of agents for imaging integrin expression in living subjects. , 2009, Cancer research.
[13] R. Schibli,et al. Influence of the molecular charge on the biodistribution of bombesin analogues labeled with the [99mTc(CO)3]-core. , 2008, Bioconjugate chemistry.
[14] Q. Le,et al. PET of EGFR Antibody Distribution in Head and Neck Squamous Cell Carcinoma Models , 2009, Journal of Nuclear Medicine.
[15] Vladimir Tolmachev,et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-ZEGFR:2377 Affibody molecule: aspect of the injected tracer amount , 2010, European Journal of Nuclear Medicine and Molecular Imaging.
[16] Sanjiv Sam Gambhir,et al. AMIDE: a free software tool for multimodality medical image analysis. , 2003, Molecular imaging.
[17] A. Santoro,et al. Analysis of epidermal growth factor receptor expression as a predictive factor for response to gefitinib (‘Iressa’, ZD1839) in non-small-cell lung cancer , 2004, British Journal of Cancer.
[18] J. Carlsson,et al. In vivo and in vitro uptake of 111In, delivered with the affibody molecule (ZEGFR:955)2, in EGFR expressing tumour cells. , 2008, Oncology reports.
[19] S. Gambhir,et al. Small-Animal PET Imaging of Human Epidermal Growth Factor Receptor Type 2 Expression with Site-Specific 18F-Labeled Protein Scaffold Molecules , 2008, Journal of Nuclear Medicine.
[20] D. A. Capretto,et al. Receptor-binding, biodistribution, and metabolism studies of 64Cu-DOTA-cetuximab, a PET-imaging agent for epidermal growth-factor receptor-positive tumors. , 2008, Cancer biotherapy & radiopharmaceuticals.
[21] J. Cassady,et al. Clinical radiation nephropathy. , 1995, International journal of radiation oncology, biology, physics.
[22] C. Vanhove,et al. SPECT Imaging with 99mTc-Labeled EGFR-Specific Nanobody for In Vivo Monitoring of EGFR Expression , 2008, Molecular Imaging and Biology.
[23] Christian Vanhove,et al. Comparison of the Biodistribution and Tumor Targeting of Two 99mTc-Labeled Anti-EGFR Nanobodies in Mice, Using Pinhole SPECT/Micro-CT , 2008, Journal of Nuclear Medicine.
[24] Sanjiv S Gambhir,et al. 124I-labeled engineered anti-CEA minibodies and diabodies allow high-contrast, antigen-specific small-animal PET imaging of xenografts in athymic mice. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[25] M. Walter,et al. Influence of different spacers on the biological profile of a DOTA-somatostatin analogue. , 2007, Bioconjugate chemistry.
[26] S. Stone-Elander,et al. On the Selection of a Tracer for PET Imaging of HER2-Expressing Tumors: Direct Comparison of a 124I-Labeled Affibody Molecule and Trastuzumab in a Murine Xenograft Model , 2009, Journal of Nuclear Medicine.
[27] E. Shpall,et al. Prognostic significance of overexpression and phosphorylation of epidermal growth factor receptor (EGFR) and the presence of truncated EGFRvIII in locoregionally advanced breast cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] M. Orditura,et al. Epidermal Growth Factor Receptor (EGFR) Expression is Associated With a Worse Prognosis in Gastric Cancer Patients Undergoing Curative Surgery , 2007, World Journal of Surgery.
[29] J. Feldwisch,et al. Evaluation of maleimide derivative of DOTA for site-specific labeling of recombinant affibody molecules. , 2008, Bioconjugate chemistry.
[30] Jacek Capala,et al. Changes in HER2 Expression in Breast Cancer Xenografts After Therapy Can Be Quantified Using PET and 18F-Labeled Affibody Molecules , 2009, Journal of Nuclear Medicine.
[31] J. Jass,et al. A simple and reproducible scoring system for EGFR in colorectal cancer: application to prognosis and prediction of response to preoperative brachytherapy , 2007, British Journal of Cancer.
[32] Steen Jakobsen,et al. Positron emission tomography (PET) imaging with [11C]-labeled erlotinib: a micro-PET study on mice with lung tumor xenografts. , 2009, Cancer research.
[33] Kenji Tada,et al. Prognostic value of epidermal growth factor receptor in patients with glioblastoma multiforme. , 2003, Cancer research.
[34] Michael M. Schmidt,et al. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.
[35] Jinha M. Park,et al. 64Cu-Labeled Affibody Molecules for Imaging of HER2 Expressing Tumors , 2010, Molecular Imaging and Biology.
[36] A. Koong,et al. Quantitative PET of EGFR expression in xenograft-bearing mice using 64Cu-labeled cetuximab, a chimeric anti-EGFR monoclonal antibody , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[37] K. Wittrup,et al. Stability and CDR composition biases enrich binder functionality landscapes. , 2010, Journal of molecular biology.
[38] R. Nicholson,et al. EGFR and cancer prognosis. , 2001, European journal of cancer.
[39] Peter S. Conti,et al. Pegylated Arg-Gly-Asp Peptide: 64Cu Labeling and PET Imaging of Brain Tumor αvβ3-Integrin Expression , 2004 .
[40] Andreas Plückthun,et al. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size. , 2010, Cancer research.
[41] R K Jain,et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. , 1995, Cancer research.